Inadequate femoral artery access causes more than 100,000 people to not address symptomatic aortic stenosis due to insufficient femoral arterial lumen sizes to undergo Transcatheter Aortic Valve Replacement (TAVR). Without treatment, the average survival is only 2-3 years.
The first is a purpose-built closure device for transcaval access in patients not eligible for traditional femoral artery access for transcatheter aortic valve replacement (TAVR). This device was co-developed with NIH in a matter of months and developed for human testing in less than two years. The Transmural Transcaval Closure Device has performed superbly and is ready for commercialization.